Compare, Analyse Sun Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs MYLAN (US) - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   MYLAN
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
MYLAN
Dec-18
SUN PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs6793,630-   
Low Rs3751,998-   
Sales per share (Unadj.) Rs121.11,670.1-  
Earnings per share (Unadj.) Rs13.445.3-  
Cash flow per share (Unadj.) Rs20.7358.1-  
Dividends per share (Unadj.) Rs2.750-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs172.61,806.7-  
Shares outstanding (eoy) m2,399.26514.50-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.41.7 258.3%   
Avg P/E ratio x39.462.0 63.5%  
P/CF ratio (eoy) x25.57.9 324.3%  
Price / Book Value ratio x3.11.6 196.1%  
Dividend payout %20.60-   
Avg Mkt Cap Rs m1,264,6501,447,610 87.4%   
No. of employees `00017.535.0 50.0%   
Total wages/salary Rs m59,6710-   
Avg. sales/employee Rs Th16,608.124,550.3 67.6%   
Avg. wages/employee Rs Th3,409.60-   
Avg. net profit/employee Rs Th1,833.8666.6 275.1%   
INCOME DATA
Net Sales Rs m290,659859,261 33.8%  
Other income Rs m10,2550-   
Total revenues Rs m300,914859,261 35.0%   
Gross profit Rs m63,076222,345 28.4%  
Depreciation Rs m17,533160,888 10.9%   
Interest Rs m5,55341,328 13.4%   
Profit before tax Rs m50,24620,130 249.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,009-3,203 -187.6%   
Profit after tax Rs m32,09323,333 137.5%  
Gross profit margin %21.725.9 83.9%  
Effective tax rate %12.0-15.9 -75.2%   
Net profit margin %11.02.7 406.6%  
BALANCE SHEET DATA
Current assets Rs m310,692479,811 64.8%   
Current liabilities Rs m173,396349,835 49.6%   
Net working cap to sales %47.215.1 312.3%  
Current ratio x1.81.4 130.6%  
Inventory Days Days9984 118.5%  
Debtors Days Days11293 119.6%  
Net fixed assets Rs m232,477166,683 139.5%   
Share capital Rs m2,399458 524.4%   
"Free" reserves Rs m411,6910-   
Net worth Rs m414,091929,564 44.5%   
Long term debt Rs m15,2261,003,298 1.5%   
Total assets Rs m646,9382,493,451 25.9%  
Interest coverage x10.01.5 675.8%   
Debt to equity ratio x01.1 3.4%  
Sales to assets ratio x0.40.3 130.4%   
Return on assets %5.82.6 224.4%  
Return on equity %7.82.5 308.8%  
Return on capital %10.23.2 319.8%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m27,4150-   
CASH FLOW
From Operations Rs m21,965178,555 12.3%  
From Investments Rs m-6,813-92,293 7.4%  
From Financial Activity Rs m-27,305-83,181 32.8%  
Net Cashflow Rs m-8,4421,479 -570.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 76.25 Rs / USD

Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SUN PHARMA With: CADILA HEALTHCARE  WYETH LTD  SHASUN PHARMA  ALEMBIC LTD  ELDER PHARMA  



Today's Market

Sensex Ends 173 Points Lower; IT and Realty Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure during closing hours today, tracking weakness in global markets owing to coronavirus outbreak.

Related Views On News

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020 (The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

One Stock that is All Charged Up for the Post Coronavirus Rebound (The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

A Safe Stock to Lockdown Now (The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak (Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

How to Trade the Coronavirus Crash - Download this FREE Report Now
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
Free Report: The Secret to Increasing Your Trading Profits Daily!
Find Out Our Top 7 Bluechips for 2020 Virtually FREE. Click Here Now!

SUN PHARMA SHARE PRICE


Apr 8, 2020 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUN PHARMA

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

OTHER USEFUL LINKS

MARKET STATS